AstraZeneca, a leading pharmaceutical company based in the UK, announced on Wednesday, March 30, 2022, that it has discontinued the production and supply of its Covid-19 vaccine, Vaxzevria.
The decision was made due to "commercial reasons" and the current surplus of updated
vaccines in the market.
The spokesperson for
AstraZeneca explained that since the development of multiple variant
Covid-19
vaccines, there has been a significant decrease in demand for Vaxzevria.
As a result, the company has ceased manufacturing and supplying the
vaccine.
Vaxzevria was one of the first
Covid-19
vaccines to be authorized and distributed globally during the pandemic.
However, with the emergence of new and more effective
vaccines, the demand for Vaxzevria has dwindled.
The spokesperson did not provide any further details on the commercial reasons behind the decision.
The discontinuation of Vaxzevria comes as the world continues to grapple with the ongoing
Covid-19 pandemic and the emergence of new variants.
The availability of updated and more effective
vaccines is crucial in the fight against the virus, and the surplus of these
vaccines has led to a decline in demand for older
vaccines like Vaxzevria.
In summary,
AstraZeneca, a British pharmaceutical company, has announced the discontinuation of its
Covid-19
vaccine, Vaxzevria, due to commercial reasons and a surplus of updated
vaccines in the market.
The
vaccine, which was one of the first to be authorized and distributed during the pandemic, is no longer being manufactured or supplied.
The decision was made as a result of the decline in demand for Vaxzevria and the availability of more effective and updated
vaccines.